DNA X entered a financing with DNA Holdings to raise $8.1 million through a private placement of Series B Convertible Preferred Stock, comprising $5.0 million in cash and cancellation of $3.1 million of a recent note. The preferred shares automatically convert to common stock after stockholder approval at the $6.00 stated value, subject to adjustments, with proceeds for working capital and general purposes. Concurrently, DNA X granted registration rights for the conversion shares to support investor liquidity. At closing, the company also plans an advisory agreement with DNA Holdings, Scott Walker and Brock Pierce for platform promotion, with 2.494 million shares to be issued after stockholder approval.
Agreement 1: DNA X Raises $8.1 Million Via Series B Preferred; $5.0 Million Cash, $3.1 Million Note Cancelled
- Agreement type: Securities Purchase Agreement for Series B Convertible Preferred Stock private placement
- Counterparty: DNA Holdings Venture
- Signed / Effective: Jun 29 2026 / Jun 29 2026
- Duration / Termination: At will
- Reason: Strengthen liquidity for working capital and growth
Agreement 2: DNA X Grants Registration Rights for Series B Conversion Shares to DNA Holdings
- Agreement type: Registration Rights Agreement for resale of conversion shares
- Counterparty: DNA Holdings Venture
- Signed / Effective: Jun 29 2026 / Jun 29 2026
- Duration / Termination: Until all registrable shares resold
- Reason: Provide liquidity pathway for investor
Agreement 3: DNA X Plans Advisory Pact With DNA Holdings, Scott Walker and Brock Pierce for 2.49M Shares
- Agreement type: Advisory and promote consulting agreement with equity compensation
- Counterparty: DNA Holdings Venture; Scott Walker; Brock Pierce
- Duration / Termination: Term plus 1-year non-compete
- Reason: Promote and develop the DNA-X platform
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.